Labetalol Versus Nifedipine as Antihypertensive Treatment for

Oral nifedipine versus intravenous labetalol for acute blood pressure control in hypertensive emergencies of pregnancy: a randomized controlled trial - Document - Gale Academic OneFile

Frontiers Management of Hypertensive Crises in Children: A Review of the Recent Literature

Lesson: Review of Hypertension in Pregnancy for Pharmacists

Full article: Oral nifedipine may be a preferential option for treating acute severe hypertension during pregnancy: a meta-analysis

Pharmacokinetics of the most commonly used antihypertensive drugs throughout pregnancy methyldopa, labetalol, and nifedipine: a systematic review

Oral nifedipine versus intravenous labetalol in hypertensive urgencies and emergencies of pregnancy: a randomized clinical trial - B Sathya Lakshmi, Papa Dasari, 2012

Methyldopa versus nifedipine or no medication for treatment of chronic hypertension during pregnancy: A multicenter randomized clinical trial - ScienceDirect

Effectiveness of nifedipine compared with other antihypertension on hypertension during pregnancy

Intravenous labetalol versus oral nifedipine for acute hypertension in pregnancy: effects on cerebral perfusion pressure - ScienceDirect

Oral nifedipine vs. intravenous labetalol for treatment of pregnancy‐induced severe pre‐eclampsia - Shi - 2016 - Journal of Clinical Pharmacy and Therapeutics - Wiley Online Library

Drugs for treatment of very high blood pressure during pregnancy - Duley, L - 2013

Oral Antihypertensives for Nonsevere Pregnancy Hypertension: Systematic Review, Network Meta- and Trial Sequential Analyses

Comparing the efficacy of oral labetalol with oral amlodipine in achieving blood pressure control in women with postpartum hypertension: randomized controlled trial (HIPPO study—Hypertension In Pregnancy & Postpartum Oral-antihypertensive therapy

Oral antihypertensive regimens (nifedipine retard, labetalol, and methyldopa) for management of severe hypertension in pregnancy: an open-label, randomised controlled trial - The Lancet